IQVIA (NYSE:IQV) Updates FY 2026 Earnings Guidance

Posted by George Bondi on Jul 28th, 2026

IQVIA (NYSE:IQV – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 12.800-13.000 for the period, compared to the consensus estimate of 12.570. The company issued revenue guidance of $17.3 billion-$17.5 billion, compared to the consensus revenue estimate of $17.3 billion.

IQVIA Stock Performance

IQV traded up $30.43 during trading on Tuesday, reaching $243.66. 876,028 shares of the company’s stock were exchanged, compared to its average volume of 1,782,506. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $247.72. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $40.67 billion, a P/E ratio of 30.16, a PEG ratio of 1.87 and a beta of 1.20. The business has a 50 day moving average price of $189.02 and a 200 day moving average price of $186.85.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts predict that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $225.71.

Read Our Latest Research Report on IQV

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

Positive Sentiment: Q2 earnings and revenue exceeded estimates. IQVIA reported adjusted earnings of $3.15 per share, above the $3.02-$3.03 analyst consensus and up from $2.81 a year earlier. Revenue increased 8.7% year over year to $4.37 billion, surpassing the $4.30 billion estimate. IQVIA Holdings Q2 Earnings and Revenues Beat Estimates
Positive Sentiment: Management raised its full-year profit forecast. IQVIA now expects fiscal 2026 earnings per share of $12.80-$13.00, above the $12.57 consensus estimate. Revenue guidance of $17.3-$17.5 billion was also maintained at or above expectations, signaling confidence in demand and execution. IQVIA Raises Annual Profit Forecast on Clinical Research Demand
Positive Sentiment: Clinical research demand and backlog are supporting growth. Reports highlighted sustained customer demand and a ballooning backlog, which could provide future revenue visibility for IQVIA’s clinical research and healthcare intelligence businesses. IQVIA Stocks Rises on 2Q Gains and Ballooning Backlog
Neutral Sentiment: IQVIA’s shares are near their 52-week high after the results, while the stock trades at roughly 30 times earnings and carries a debt-to-equity ratio of about 2.2. The strong outlook is supportive, but the valuation and leverage may limit further upside if growth or margins disappoint.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Gilpin Wealth Management LLC purchased a new stake in IQVIA during the 4th quarter valued at $27,000. CrossGen Wealth LLC purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $28,000. Measured Wealth Private Client Group LLC purchased a new stake in IQVIA in the third quarter worth approximately $30,000. Johnson Financial Group Inc. purchased a new stake in IQVIA during the 3rd quarter valued at $52,000. Finally, DV Equities LLC purchased a new position in shares of IQVIA in the 4th quarter worth $53,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

(Get Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.